

# Full A Call for Consensus in Defining Efficacy in Clinical Trials for Opioid Addiction: Combined Results from a Systematic Review and Qualitative Study in Patients Receiving Pharmacological Assisted Therapy for Opioid Use Disorder

**Brittany B. Dennis**

McMaster University

**Nitika Sanger**

McMaster University

**Monica Bawor**

St. George's University of London

**Leen Naji**

McMaster University

**Andrew Worster**

McMaster University

**Natasha Baptist-Mohseni**

McMaster University

**Alannah Hillmer**

McMaster University

**Danielle Rice**

Ottawa health research institute

**Kim Corace**

Royal Ottawa Mental Health Centre

**Brian Hutton**

Ottawa Health Research Institute

**Peter Tugwell**

Ottawa Hospital Research Institute

**Lehana Thabane**

McMaster University

**Zainab Samaan** (✉ [samaanz@mcmaster.ca](mailto:samaanz@mcmaster.ca))

McMaster University <https://orcid.org/0000-0002-5974-9361>

**Keywords:** Opioid addiction; clinical trials; efficacy; methodology; patient important outcomes; treatment effectiveness

**Posted Date:** February 21st, 2019

**DOI:** <https://doi.org/10.21203/rs.2.382/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on January 6th, 2020. See the published version at <https://doi.org/10.1186/s13063-019-3995-y>.

# Abstract

**Background** Given the complex nature of opioid addiction treatment and the rising number of available opioid substitution and antagonist therapies (OSAT), there is no ‘gold standard’ measure of treatment effectiveness, and each successive trial measures a different set of outcomes which reflect success in arbitrary or opportune terms. We sought to describe the variation in current outcomes employed across clinical trials for opioid addiction, as well as determine whether a discrepancy exists between the treatment targets that patients consider important and how treatment effectiveness is measured in the literature. **Methods** We searched nine commonly used databases (e.g. EMBASE, MEDLINE) from inception to August 1, 2015. Outcomes used across trials were extracted and categorized according to previously established domains. To evaluate patient reported goals of treatment, semi-structured interviews were conducted with 18 adults undergoing methadone treatment. **Results** We identified 60 trials eligible for inclusion. Once outcomes were categorized into eight broad domains (e.g. abstinence/substance abuse), we identified 21 specific outcomes with furthermore 53 subdomains and 118 measurements. Continued opioid use and treatment retention were the most commonly reported measures (46%, n=28). The majority of patients agreed that abstinence from opioids was a primary goal in their treatment, however they also stressed goals under-reported in clinical trials. **Conclusion** There is inconsistency in the measures used to evaluate the effectiveness of OSATs. Individual and population level decision making is being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important. PROSPERO ID CRD42013006507

## Background

Information retrieved from the highest quality evidence – most often from randomized controlled trials (RCTs)—is used to inform health care decisions at individual and population levels. From the development of research questions to decisions regarding “significant” treatment targets, researchers control evidence generation in its entirety. We rely on their expert opinion to design studies and trust they select the appropriate outcomes reflecting treatment success. Despite best interests, the value of many pharmacological interventions is commonly evaluated on their observed effect across different biochemical and surrogate measurements.<sup>1</sup> Frequently these measurements neither reflect nor acknowledge the values and preferences of the populations they are meant to serve. Patient important outcomes reflect the health concerns, fears regarding adverse drug reactions, treatment goals, and overall values of patient populations. These outcomes are often underrepresented in comparison to biologic measurements closely associated with the physiologic disease process.<sup>1</sup> For instance, the majority of trials within the diabetes literature include primary endpoints such as blood glucose level as an indicator of efficacy due to its direct relation to the pathophysiology of diabetes. Outcomes such as death, stroke, infection, pain function, or delayed wound healing have significant impact on patients’ lives, yet are often underreported.<sup>2</sup> Unfortunately, patient important outcomes are often neglected in trials aimed to establish treatment benefit; this deficit is of substantial concern to the growing evidence base in opioid addiction; known formally as opioid use disorder (OUD).<sup>3</sup>

Given the complex nature of OUD treatment and the rising number of available pharmacological opioid substitution and antagonist therapies (OSAT), there is no 'gold standard' measure of treatment effect and each successive trial measures a different set of treatment outcomes which reflect success in arbitrary or opportune terms.<sup>4-6</sup> Commonly included endpoints comprise attrition rates, illicit substance use, presence of medical and psychiatric comorbidity, social function as measured by current housing arrangements, collective neighborhood income, educational achievement, employment, and involvement in criminal activity.<sup>4,7,8</sup> The variation in the selection of outcomes as well as the marked range of definitions, instruments, and measurements of specific outcomes demand the need for further research to establish a summary of the current outcomes utilized in the literature, as well as determine which outcomes reflect patient's values and preferences for the end goals of addiction treatment.

In the current study, we sought to outline the current outcomes employed in clinical trials for opioid addiction, as well as to determine whether a divide exists between the treatment targets patients consider important and those selected to evaluate efficacy in the literature.

## Methods

This study was completed using a mixed-methods design in two phases. In the first phase of the study we completed a systematic review which aimed to describe outcomes used in the current literature to establish effectiveness of different OSATs. The second phase aimed to determine patient's perspectives of successful addiction treatment with emphasis on the patient's end-goals of therapy. Phase 1 of this study used the previously published protocol for a systematic review and network meta-analysis comparing OSAT interventions for OUD during which we also extracted the listing of outcomes reported within each study.<sup>9</sup> The literature search was completed in August 2015; this was not updated for the current study given that the emphasis is not on establishing a superior therapy for addiction, but rather to provide a summary of the outcome measures employed across clinical trials comprising the main body of evidence.

### Phase 1: Systematic Review to Establish Outcomes Used in the Current Literature

#### *Methodology*

We performed a systematic review to identify all OSAT trials. A greater detail of our study methods can be found in the published protocol.<sup>10</sup> This study was registered in the PROSPERO database (CRD42013006507) and adheres to the PRISMA guidelines.<sup>11</sup>

Studies were limited to trials evaluating pharmacological therapies for opioid addiction in general addiction populations, any studies in special populations including prison were excluded. No studies were eliminated based on outcome selection. We also contacted all primary investigators listed on the NIH Clinical Trial Registry from eligible studies identified during the title screening to inform them of this review and inquire for information regarding any publications resulting from their trials. This review placed no constraints on language or date of publication. Animal studies and incomplete studies (pilot,

preliminary reports) were excluded. Studies without comparison groups were also excluded (i.e. case-report or case-series). Methodological quality assessment was conducted using the Cochrane Risk of Bias Tool for RCTs.

### *Summary of Outcomes Used Across OSAT Trials*

The primary aim of the current study was to summarize all outcome domains, subdomains and their definitions and outcomes measurements/instruments used for each outcome in trials of OSAT for OUD. Data extraction forms were constructed and pilot tested for use in this review. We abstracted the sample size, mean age, eligibility criteria, intervention description, dose, approaches to missing data, outcome definition, outcome measurement, covariates included in regression models if adjusted analyses were performed, and the statistical association reported (e.g. Odds Ratio[OR], Relative Risk [RR]).

To provide an organized summary, we structured outcomes into broader categories according to the domains proposed by commonly used measurement scales evaluating addiction severity (i.e., the Addiction Severity Index [ASI]<sup>12</sup> and Maudsley Addiction Profile [MAP]).<sup>13</sup> These tools evaluate treatment response using the broader domains of substance use behavior, physical and mental health, and social functioning.<sup>12,13</sup> Both tools are practical and provide a global assessment of patients' physical and social functioning. Our outcome domains included physical health, psychiatric health and symptoms, abstinence and substance use behavior, and personal and social functioning. Some studies used additional outcomes that did not conform to these domains; thus, we included global quality of life and addiction severity assessments (including global addiction severity, intervention adherence, acceptance of intervention, and resource utilization (e.g. hospital admission) as additional domains. This categorization of outcome domains and subdomains provides researchers and clinicians with an overview of the current outcomes used to assess patients' response to OSAT.

All outcomes used across trials included in this review were extracted and categorized according to the above described criteria.

## **Phase 2: Qualitative Interviewing of Patients on Pharmacological Treatment for OUD**

### *Recruitment and Interview Methodology*

Patients were recruited from two opioid addiction treatment centers in Ontario, Canada using purposive sampling. The research collaborative between the Population Genomics Program at McMaster University and the Canadian Addiction Treatment Centers (CATC) provided a framework for study recruitment, data collection, data analysis, and follow-up. Eligibility criteria included: patients  $\geq 18$  years, currently receiving an opioid substitution therapy including methadone maintenance treatment or buprenorphine, able to understand and speak English and able to provide informed consent.<sup>16</sup> The Hamilton Integrated Research Ethics Board (HiREB) approved this study (HiREB Study ID 0168). This study adheres to the STROBE guidelines.<sup>17</sup>

Qualitative methods were used to establish patients' perspectives of successful addiction treatment. Structured open-ended interviews were conducted to explore each patient's end-goals of therapy. These interviews identified common themes with regard to addiction treatment goals. The interviews were transcribed and analyzed for themes, clarifications, and deeper understanding of the topics outlined above.<sup>16</sup>

Convenience sampling was utilized between two addiction treatment clinics. Recruiting from two separate sites allowed for a broader patient demographic to be covered, as socioeconomic status and homelessness rates were known to differ between sites. Flyers advertising the study were posted at both clinical sites. All patients eligible for recruitment were also approached and informed about the study objectives by the clinic's healthcare staff. Upon gaining informed consent, patients were given a demographic questionnaire and interviewed by two investigators using structured questions and open-ended questions. No one else was present at these interviews. All patients included in the study were given a five-dollar gift card at the end of the interview.<sup>16</sup>

Interviews were conducted by an addiction specialist nurse Carolyn Platter (BScNurs), and two female research coordinators, Julia Woo (BHSc) and Anuja Bhalerao (BHSc). These team members have performed hundreds of interviews in this population since working with the McMaster GENOA research collaborative. The interviewers were selected in efforts to minimize potential bias generated during data collection. These team members had no previous stake in the research question or design of this study. All interviewers underwent ethics and sensitivity training prior to meeting the patients, as per McMaster University Research Ethics Board Guidelines. Each team member has completed the Tri-Council Policy Statement course. The patients recruited into the study had not been previously interviewed by the team members and we are confident there was no relationship between participants and interviewers prior to the interview. Participants were briefed as to the goals of the study, particularly our aim of establishing whether current research accurately reflects what they wish to gain from treatment.

Interviews were completed using a structured piloted questioning tool with prompts, patients were approached allowing for open ended answers. Each interview was audio recorded for later transcription. Each interviewer also made field notes, which were used to aid in later transcription. Each interview transcript was carefully investigated for insight into the major research question, "How would you measure success in methadone maintenance or buprenorphine treatment?" We also provided patients a list of commonly anticipated treatment goals and asked them to rank which aspect of recovery meant the most to their addiction treatment. Patients were allowed to rank up to four items. The list provided a summary of different potential goals across substance abuse, physical health, emotional stability, and personal functioning domains. A register of these goals can be found in the Supplementary Web Appendix. The interviews lasted approximately 40 minutes and were conducted on site at the treatment facility between the dates of September 2015 and February 2016. Interviews were conducted until responses to the major research questions were saturated, having no new themes emerge.<sup>16</sup> Patients were not provided transcribed copies of interview.

## *Analysis*

Interviews were transcribed and evaluated for the common definitions of success in addiction treatment as well as aspects of recovery patients found important. Two primary interviewers (AB, JW) were responsible for coding the data, unaided software. This process was later reviewed by all members of the team. These responses were coded according to the broader domains proposed by popular measurement scales evaluating addiction severity; the ASI<sup>12</sup> and MAP.<sup>13</sup> Additional domains not included in the MAP or ASI were also added. These domains included global quality of life and addiction severity assessments (including global addiction severity measure scores), intervention adherence, acceptance of intervention, and resource utilization (e.g., hospital admission).<sup>16</sup>

Due to small size and limited power of our sample, no statistical tests were conducted in reference to significant differences between the participants at the two sites.<sup>16</sup>

## **Results**

### **Phase I: Findings from the Systematic Review**

An annotated flow diagram of the study selection process is presented in [Figure 1](#). We searched databases since inception to August 1, 2015 and identified 6,077 articles. We identified 60 trials with a combined participant sample of 13341 patients eligible for full text-extraction.<sup>19-78</sup> A summary of the included trials is available in the Supplementary Web Appendix. [Table 1](#) summarizes the outcome domains and sub-domains used across trials included in this study; the outcomes are categorized into broad domains, outcome domains, subdomains and the specific measurements. Within the 8 broadest domains (abstinence and substance use behavior, physical health, psychiatric health and symptoms, personal and social functioning, resource utilization, intervention adherence, intervention acceptance, and global quality of life and addiction severity), there are 21 more specific outcome domains (e.g., illicit opioid use, illicit non-opioid substance use), and across these outcomes there exists 53 separate definitions or measurements.

Of the 60 trials eligible for inclusion to this review, retention in treatment was the most commonly measured and reported outcome. Of the 28 studies reporting retention in treatment as their primary outcome, 16 different interventions were evaluated. The second most commonly reported outcome was illicit opioid use, which took 17 definitions and a further eight variations in measurement.

### **Phase II: Qualitative Interviewing of Patients on Pharmacological Treatment for Opioid Addiction**

A total of 18 individuals from two treatment centers participated in this study. Sixteen of the participants were currently undergoing MMT at the time of recruitment and 2 participants were receiving buprenorphine but had received MMT at least one year prior. The mean age of the participants was 36.11 (SD=10.01) years with majority female (67%) and of Caucasian ethnicity (89%). Participants in one site had a higher mean income (\$48,750 vs \$35,000) and were more likely to be employed (63% vs 40%)

when compared to the second site's participants which is expected and selected purposefully to be economically different. All participants were interviewed in a single session, no repeated sessions were necessitated during the course of this study.

### ***Qualitative Interview***

The majority of participants (61.1%) identified their main goal of methadone treatment as being abstinent from drugs. This goal was clearly indicated by patients, including statements like: "Just being completely off of drugs. To never touch drugs again". Close to a third of these individuals had a more specific goal of being off of methadone completely (38%). One participant stated specifically (as seen in the following direct quote) that even though they are sober, their ultimate goal is to be "clean" from all opioids.

*"When someone tells me I'm not sober because I'm on methadone. I tell them I may not be clean because I'm putting this medication in my body but I am sober. I want to be clean. To me, I'm sober right now, I have been sober for two and a half years. I haven't touched the drugs for two and a half years. At the end of it, I want to be off the methadone completely but I want to be able to taper down till I no longer need it anymore and I want to look back and say that was just a phase in my life. I took the necessary steps to make myself better and I accomplished that. And all the things that I accomplished being on methadone too. So yeah, I just want to get off of it completely, eventually"*

Others did not desire to be off methadone and specified methadone was helping them. One participant's main goal was for pain control and not to be off methadone, as it helped them function and be able to move. When asked if they were hoping to get completely off methadone they responded saying, "I don't know if I ever will. I see my doses being reduced but until my health problems are resolved, I have absolutely no problem being on it if it has to be for the rest of my life."

Other goals of methadone treatment that were not as common included being able to get back to their usual lives and able to maintain it, to not be sick and to manage addictions not only related to drugs but addictions in other domains of their life. Participant's verbatim responses are summarized in [Table 2](#).

### ***Response to predetermined treatment goals***

Seventeen out of the 18 participants completed section indicating which aspect of recovery meant the most to their addiction treatment. Please refer to [Figure 2](#) for a graphical summary of patients' first ranked treatment goals.

Abstinence from opioid use was the most commonly selected outcome overall followed by stability of relationships, reduced money spent on drugs, reduced drug craving, employment, regaining physical health, pain control, coping, reduced depression, stable housing, improved sexual function, decreased risk of overdose, reduced injecting and reduced anxiety overall across all participants' four outcome choices. The most commonly selected primary outcome for participants was abstinence from opioid use, with 47% (8) of participants selecting it as their first choice. 16.6% (3) chose money spent on drugs as their second most important outcome. Participant's outcomes are summarized in [Table 3](#).

## Discussion

Findings from this study outline the current outcomes employed in clinical trials for opioid addiction, and also provide a unique insight into the treatment goals patients consider important when receiving pharmacological therapies for OUD.

Results from this systematic review highlight a major lack of consensus in our evidence base when determining appropriate end-points for establishing treatment effectiveness in OUD. A substantial number of outcomes as well as variations in the definitions and measurements of the same outcomes were reported across trials. Despite the overwhelming collection of outcomes employed by trialists, substance use—specifically opioid—and treatment retention remain the most consistently reported. Trialists seldom explored pharmacological effect on personal and social functioning outcomes such as criminal behavior, employment, relationships, and personal stability end-points including type of accommodation (20%, n=12).

The most commonly employed outcomes used to establish effectiveness were in stark contrast to the goals for treatment patients described in the qualitative interviews performed for the second phase of our study. While the majority of patients agreed that abstinence and reduction in opioid use was a primary goal in their treatment, they also stressed goals for therapy comprising employment, improved relationship stability, reduction in the money spent on drugs, as well as the improvement in physical and psychiatric symptoms such as pain, depression, and anxiety. Regrettably, these outcomes were rarely reported or of primary focus in the clinical trials.

When assessing the comparative effectiveness of all interventions among patients receiving OSATs, retention in treatment was the most consistently measured and reported outcome across trials (46%, n=28). In direct contrast to staying on treatment, our interviews with patients demonstrate an eagerness to complete therapy and get off the methadone treatment regime as a recurrent theme.

Outcome selection bears serious implications for the interpretation of the results as well as our ability to extrapolate such findings in a wider clinical context. These methodological shortcomings highlight the need for new assessment strategies for opioid addiction treatment options, where future efforts should consider targeting the objective assessment of treatment effectiveness employing long-term follow-up using administrative data-linkage for trial participants to evaluate hard long-term outcomes such as incidence of hepatitis, HIV, cardiovascular abnormalities, and mortality. Among the trials included in this review, three evaluated the impact of interventions on mortality<sup>47,79</sup> or cardiac function.<sup>50</sup>

Trials evaluating OSATs suffer from poor methodological quality. A combination of small sample size, poor design, highly stringent eligibility criteria, effect estimates with tremendous imprecision, short-follow up time, missing data, and a major lack of consensus over patient-important outcomes has led to an accumulation of a large yet very weak body of evidence. Whether it be illicit opioid use or risky behavior, the large number of definitions and measurements used to assess the same attribute suggest the need for more consensus in the field and understanding of what treatment outcomes are most important to addiction patients.

# Conclusions

In agreement with current guidelines, our study demonstrates there is limited consistency in the evidence used to evaluate the effectiveness of OSATs.<sup>8081</sup> More concerning, our treatment recommendations and clinical decisions are being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important. This is a substantial limitation in the literature. Without the identification of a measurable treatment outcome that has an impact and significance to patients, services, and the population as a whole, all the investment in trials will result in inadequate and inconsistent “efficacy” with limited, if any, external validity. We demonstrate here the need for an established set of OSAT outcomes guided by all stakeholders to inform clinicians of the true efficacy of these therapies and guide trialists to ensure our future understanding of these treatments accurately reflects the priorities of our patient population.

# References

1. Deshpande, P. R., Rajan, S., Sudeepthi, B. L. & Abdul Nazir, C. P. Patient-reported outcomes: A new era in clinical research. *Perspect. Clin. Res.* **2**, 137–44 (2011).
2. Montori, V. M., Wang, Y. G., Alonso-Coello, P. & Bhagra, S. Systematic evaluation of the quality of randomized controlled trials in diabetes. *Diabetes Care* **29**, 1833–1838 (2006).
3. *Diagnostic and statistical manual of mental disorders (5th ed.)*. (American Psychiatric Publishing, 2013).
4. Mattick Richard, P., Breen, C., Kimber, J. & Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews* (2009). doi:10.1002/14651858.CD002209.pub2
5. Hedrich, D. *et al.* The effectiveness of opioid maintenance treatment in prison settings: a systematic review. *Addiction* **107**, 501–517 (2012).
6. Li, Y., Kantelip, J.-P., Gerritsen-van Schieveen, P. & Davani, S. Interindividual variability of methadone response. *Mol. Diagn. Ther.* **12**, 109–124 (2008).
7. Hedrich, D. *et al.* The effectiveness of opioid maintenance treatment in prison settings: a systematic review. *Addiction* **107**, 501–517 (2012).
8. Li, Y., Kantelip, J.-P., Gerritsen-van Schieveen, P. & Davani, S. Interindividual variability of methadone response. *Mol. Diagn. Ther.* **12**, 109–124 (2008).
9. Dennis Brittany Burnsand Naji, L. and B. M. and B. A. and V. M. and D. J. and P. C. and P. G. and M. D. C. and W. A. and D. D. and S. Z. and T. L. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. *Syst. Rev.* **3**, 105 (2014).
10. Dennis, B. B. *et al.* The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. *Syst Rev* **3**, 105 (2014).

11. Shamseer, L. *et al.* Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. *BMJ (Online)* **349**, (2015).
12. McLellan, A. T. *et al.* The fifth edition of the Addiction Severity Index. *J. Subst. Abuse Treat.* **9**, 199–213 (1992).
13. Marsden, J. *et al.* The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. *Addiction* **93**, (2002).
14. Sinha, R., Fuse, T., Aubin, L.-R. & O'Malley, S. S. Psychological stress, drug-related cues and cocaine craving. *Psychopharmacology (Berl)*. **152**, 140–148 (2000).
15. Morissette, A., Ouellet-Plamondon, C. & Jutras-Aswad, D. Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance/Le craving comme symptome central de la toxicomanie: de ses fondements neurobiologiques a sa pertinence clinique. *Sante Ment. Que.* **39**, 21–38 (2014).
16. Woo, J. *et al.* "Dont judge a book by its cover": A qualitative study of methadone patients' experiences of stigma. *Subst. Abuse. Res. Treat.* (2017). doi:10.1177/1178221816685087
17. von Elm, E. *et al.* Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* **335**, 806–808 (2007).
18. Dennis, B. B. *et al.* Opioid substitution and antagonist therapy trials exclude the common addiction patient: A systematic review and analysis of eligibility criteria. *Trials* **16**, 1 (2015).
19. Ahmadi, J. & Ahmadi, K. Controlled trial of maintenance treatment of intravenous buprenorphine dependence. *Ir J Med Sci* **172**, 171–173 (2003).
20. van den Brink, W. *et al.* Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. *BMJ* **327**, 310 (2003).
21. Ling, W., Wesson, D. R., Charuvastra, C. & Klett, C. J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psychiatry* **53**, 401–407 (1996).
22. Schottenfeld, R. S., Chawarski, M. C. & Mazlan, M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. *Lancet* **371**, 2192–2200 (2008).
23. Johnson, R. E. *et al.* A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. *Drug Alcohol Depend* **40**, 17–25 (1995).
24. Ahmadi J Moosavinasab M, Babae M, Firoozabadi A, Mohagheghzadeh M., et al, F. H. Treatment of heroin dependence. *Ger. J. Psychiatry* **7**, 1–5 (2004).
25. Ahmadi, J. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. *Drug and Alcohol Dependence* **66**, 111–114 (2002).
26. Yancovitz, S. R. *et al.* A randomized trial of an interim methadone maintenance clinic. *Am J Public Heal.* **81**, 1185–1191 (1991).
27. Sees, K. L. *et al.* Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. *JAMA* **283**, 1303–1310 (2000).

28. Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *Am J Psychiatry* **151**, 1025–1030 (1994).
29. Soyka, M., Zingg, C., Koller, G. & Kuefner, H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. *Int J Neuropsychopharmacol* **11**, 641–653 (2008).
30. March, J. C., Oviedo-Joekes, E., Perea-Milla, E. & Carrasco, F. Controlled trial of prescribed heroin in the treatment of opioid addiction. *Journal of Substance Abuse Treatment* **31**, 203–211 (2006).
31. Comer, S. D. *et al.* Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* **63**, 210–218 (2006).
32. Eder, H. *et al.* Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. *Addiction (Abingdon, England)* **100**, 1101–1109 (2005).
33. Eissenberg, T. *et al.* Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. *JAMA* **277**, 1945–1951 (1997).
34. Jaffe, J. H. *et al.* Methadyl acetate vs methadone. A double-blind study in heroin users. *JAMA* **222**, 437–442 (1972).
35. Kamien, J. B., Branstetter, S. A. & Amass, L. Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. *Heroin Addiction and Related Clinical Problems* **10**, 5–18 (2008).
36. King, V. L. *et al.* A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. *J Subst Abus. Treat* **31**, 385–393 (2006).
37. Oviedo-Joekes, E. *et al.* Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. *N. Engl. J. Med.* **361**, 777–786 (2009).
38. Oviedo-Joekes, E., March, J. C., Romero, M. & Perea-Milla, E. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. *Drug Alcohol Rev* **29**, 75–80 (2010).
39. Potter, J. S. *et al.* Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). *J Stud Alcohol Drugs* **74**, 605–613 (2013).
40. Robertson, J. R. *et al.* Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial. *Addiction* **101**, 1752–1759 (2006).
41. Saxon, A. J. *et al.* Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug Alcohol Depend* **128**, 71–76 (2013).
42. Anglin, M. D., Conner, B. T., Annon, J. & Longshore, D. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. *Addiction* **102**, 1432–1442 (2007).
43. Schwartz, R. P., Kelly, S. M., O’Grady, K. E., Gandhi, D. & Jaffe, J. H. Interim methadone treatment compared to standard methadone treatment: 4-month findings. *J Subst Abus. Treat* **41**, 21–29

- (2011).
44. Schwartz, R. P. *et al.* A randomized controlled trial of interim methadone maintenance. *Arch Gen Psychiatry* **63**, 102–109 (2006).
  45. Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. *Journal of clinical psychopharmacology* **16**, 58–67 (1996).
  46. Wolstein, J. *et al.* A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. *Pharmacopsychiatry* **42**, 1–8 (2009).
  47. Ling, W., Charuvastra, V. C., Kaim, S. C. & Klett, C. J. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. *Arch. Gen. Psychiatry* **33**, 709–720 (1976).
  48. White, J. M. *et al.* Relationship between LAAM-methadone preference and treatment outcomes. *Drug Alcohol Depend* **66**, 295–301 (2002).
  49. Kosten, T. R., Schottenfeld, R., Ziedonis, D. & Falcioni, J. Buprenorphine versus methadone maintenance for opioid dependence. *J Nerv Ment Dis* **181**, 358–364 (1993).
  50. Wedam, E. F., Bigelow, G. E., Johnson, R. E., Nuzzo, P. A. & Haigney, M. C. P. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. *Arch. Intern. Med.* **167**, 2469–2475 (2007).
  51. Woody, G. E. *et al.* Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. *JAMA* **300**, 2003–2011 (2008).
  52. Kakko, J., Svanborg, K. D., Kreek, M. J. & Heilig, M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet* **361**, 662–668 (2003).
  53. Fischer, G. *et al.* Buprenorphine versus methadone maintenance for the treatment of opioid dependence. *Addiction (Abingdon, England)* **94**, 1337–1347 (1999).
  54. Krook, A. L. *et al.* A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. *Addiction* **97**, 533–542 (2002).
  55. Ling, W. *et al.* Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. *Addiction* **93**, 475–486 (1998).
  56. Lintzeris, N. *et al.* Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. *Am J Addict* **13 Suppl 1**, S29-41 (2004).
  57. Mattick, R. P. *et al.* Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. *Addiction* **98**, 441–452 (2003).
  58. Neri, S. *et al.* Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. *Psychopharmacology* **179**, 700–704 (2005).

59. Shufman, E. N. *et al.* The efficacy of naltrexone in preventing reabuse of heroin after detoxification. *Biological psychiatry* **35**, 935–945 (1994).
60. Pani, P. P., Maremmani, I., Pirastu, R., Tagliamonte, A. & Gessa, G. L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. *Drug Alcohol Depend* **60**, 39–50 (2000).
61. Schottenfeld, R. S., Pakes, J. R. & Kosten, T. R. Prognostic factors in Buprenorphine- versus methadone-maintained patients. *J Nerv Ment Dis* **186**, 35–43 (1998).
62. Preston, K. L., Umbricht, A. & Epstein, D. H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. *Arch Gen Psychiatry* **57**, 395–404 (2000).
63. Schottenfeld, R. S. *et al.* Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. *Am J Psychiatry* **162**, 340–349 (2005).
64. Fudala, P. J. *et al.* Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med* **349**, 949–958 (2003).
65. Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Dose-response effects of methadone in the treatment of opioid dependence. *Annals of internal medicine* **119**, 23–27 (1993).
66. Hartnoll, R. L. *et al.* Evaluation of heroin maintenance in controlled trial. *Arch Gen Psychiatry* **37**, 877–884 (1980).
67. Strang, J. *et al.* Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. *Lancet* **375**, 1885–1895 (2010).
68. Zaks, A., Fink, M. & Freedman, A. M. Levomethadyl in maintenance treatment of opiate dependence. *JAMA: the journal of the American Medical Association* **220**, 811–813 (1972).
69. Strain, E. C., Bigelow, G. E., Liebson, I. A. & Stitzer, M. L. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. *JAMA* **281**, 1000–1005 (1999).
70. Petitjean, S. *et al.* Double-blind randomized trial of buprenorphine and methadone in opiate dependence. *Drug Alcohol Depend* **62**, 97–104 (2001).
71. Guo, S. Efficacy of naltrexone Hydrochloride for preventing relapse among opiate dependent patients after detoxification. *Hong Kong J. Psychiatry* **11**, 2–8 (2001).
72. Krupitsky, E. M. *et al.* Naltrexone for heroin dependence treatment in St. Petersburg, Russia. *J Subst Abus. Treat* **26**, 285–294 (2004).
73. San, L., Pomarol, G., Peri, J. M., Olle, J. M. & Cami, J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. *Br J Addict* **86**, 983–990 (1991).
74. Krupitsky, E. M. *et al.* Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. *J Subst Abus. Treat* **31**, 319–328 (2006).
75. Giacomuzzi, S. M., Ertl, M., Kemmler, G., Riemer, Y. & Vigl, A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. *ScientificWorldJournal* **5**, 452–468 (2005).

76. Haasen, C. *et al.* Heroin-assisted treatment for opioid dependence: randomised controlled trial. *The British journal of psychiatry: the journal of mental science* **191**, 55–62 (2007).
77. Johnson, R. E., Jaffe, J. H. & Fudala, P. J. A controlled trial of buprenorphine treatment for opioid dependence. *JAMA: the journal of the American Medical Association* **267**, 2750–2755 (1992).
78. Krupitsky, E. *et al.* Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. *Archives of General Psychiatry* **69**, 973–981 (2012).
79. Hartnoll, R. L. *et al.* Evaluation of heroin maintenance in controlled trial. *Arch. Gen. Psychiatry* **37**, 877–884 (1980).
80. Bruneau, J. *et al.* Management of opioid use disorders: a national clinical practice guideline. *Can. Med. Assoc. J.* **190**, E247–E257 (2018).
81. *Methadone Maintenance Treatment Program Standards and Clinical Guidelines.* (The College of Physicians and Surgeons of Ontario, 2011).

## Abbreviations

**GENOA:** Genetics of opioid addiction, **OSATs:** opioid substitution and antagonist therapies, **PRISMA:** preferred reporting items for systematic reviews and meta-analyses, **HiREB:** Hamilton Integrated Research Ethics Board, **RCT:** randomized controlled trial, **OD:** opioid use disorder

## Declarations

### Ethics approval and consent to participate

Participants were recruited as part of the Genetics of Opioid Addiction (GENOA) research collaborative between McMaster University and the Population Genomics Program. GENOA is a prospective cohort investigation approved by the Hamilton Integrated Research Ethics Board. Amendments to the GENOA study protocol to include new questions as part of our interview tool to allow for qualitative interviews exploring patient important outcomes was approved (HIREB #0168).

### Consent for publication

This study does not include any individual persons data requiring consent for publication.

### Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### Competing interests

The authors declare that they have no competing interests

## Funding

This work was supported by the CIHR Drug Safety and Effectiveness Network (DSEN) grant (grant number: 126639) and CIHR (sponsor award number 156306). The funders had no role in study design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

## Authors' contributions

ZS, BD, and LT led the development of the project. BD, NS, MB, LN, CP, AW, JW, AB, NBM, AH, KC, BH, DR, PT, ZS and TB contributed to the development of the research protocol, which is published in the journal *Systematic Reviews*. BD, NS, MB, LN, CP, AW, JW, AB, NBM, AH, KC, BH, DR, PT, ZS and TB contributed to interpreting the data and writing the manuscript. ZS had full access to data from this investigation and she is accountable for the reliability of the data and the accuracy of all analyses performed.

## Acknowledgements

We would like to sincerely thank everyone who contributed to the completion of this project. We would like to specially thank Arnav Agarwal, and Joshua Kong for their initial help with the screening and data abstraction of studies. This project would not have been possible without the great collaboration cemented between GENOA and the CATC.

## Tables

**Table 1: Summary of All Clinical and Social Outcomes Used to Establish Effectiveness for Trials in Opioid Addiction**

Domains	Outcomes	Subdomains	Measurement of Outcome
<b>Abstinence and Substance Use Behaviour</b>	<i>Illicit Opioid Use</i>	Frequency of Illicit Opioid Use (Mean number of negative opioid urine screens or percentage of positive opioid screens, days of illicit use, assessed per treatment arm)	Urine toxicology screening
			A composite score from the Addiction Severity Index (European version)
			Self-report
			Hair sample toxicology screening
			Scores from Addiction Severity Index (American interview) domain assessing number of days of opiate use in last month
			Visual Analog Scale (daily heavy drug abuse was recorded as 10 and 'drug free' was recorded as 0)
			Weekly Activity Summary (WAS)
		'Dirty rate' measured using the number of opiate-positive urine screenings ÷ divided by the number of weeks of study participation	Urine toxicology screening
		Time to relapse measured using the number of days between baseline and occurrence of the first opiate-positive urine screening	Urine toxicology screening
		Failure to maintain abstinence	Urine toxicology screening
Heroin use in preceding month at three, six, and twelve month interviews	Self-reported frequency of use measured using the Opiate Treatment Index		
Response to treatment measured as a reduction of regular use of street heroin, which was defined as 50% or more of negative specimens on urinalysis during weeks	Urine toxicology screening		

Domains	Outcomes	Subdomains	Measurement of Outcome
		Percentage of patients in a drug free period, defined as time elapsed between the first day of Naltrexone administration and the first evidence of opiate abuse (day on which positive urine test for opiate was obtained, or alternatively, the day on which the patient reported on opiate abuse)	Urine toxicology screening
		Abstinence from street heroin (zero use) in the past 30 days	Self-reported abstinence obtained by independent researchers in face-to-face interviews
		Assessment of near (<2 opioid positive urine screens) and full abstinence (0 opioid positive urine screens)	Urine toxicology screening
		Percentage of participants per treatment arm who maintained 12 consecutive opioid-free urine screens	Urine toxicology screening
		Slip defined as occasional heroin use, less than three consecutive positive urine screens, and no symptoms of withdrawal	Self-report and urine toxicology screening
		Days to heroin relapse (3 consecutive opiate-positive urine screens)	Urine toxicology screening
		Number of days a patient could remain abstinent measured by the longest duration of opiate negative urine screen	Urine toxicology screening
		Drug use history and routes of substance abuse	Risk Behaviour Survey
		The global severity of all aspects of their current drug problem	Self-report on a scale of 0 (no problem) to 100 (very severe)
		Opioid relapse defined as everyday heroin use, three consecutive positive urine tests, or reported symptoms of withdrawal	Self-report and urine toxicology screening
		Degree of opioid substance abuse	Global rating scale: rating of 2 marked an improvement in rehabilitation and substance use
	<i>Non-opioid Substance Use</i>	Frequency of poly-substance use (eg. Percentage/mean number of positive stimulants/benzodiazepines urine screens per treatment arm cocaine, benzodiazepines, illicit methadone)	Self-report
Reported by family members or friends watching the participant			
Weekly Activity Summary (WAS)			
Visual Analog Scale (daily heavy drug abuse was recorded as 10 and 'drug free' was recorded as 0)			
Weekly Drug Use Questionnaire			

Domains	Outcomes	Subdomains	Measurement of Outcome
			Urine toxicology screening
		Days of alcohol use per treatment arm	Self-report
		Severity of nicotine dependence	The Fagerström Test for Nicotine Dependence
		Alcohol consumption	Breathalyser test
		The global severity of all aspects of their current drug problem	Measured on a scale of 0 (no problem) to 100 (very severe)
		Drug use history and routes of substance abuse	Risk Behaviour Survey
	<i>Health Risk Behaviour Related to Substance Use</i>	Injecting drug-use behaviour Reduction in HIV risk behaviours	Self-report
			AIDS risk inventory
			Opiate Treatment Index
			Risk Assessment Battery (RAB) scores Maudsley Addiction Profile
	<i>Money Spent or Gained on Illicit Opioid Consumption</i>	Amount of money spent on illicit opioid consumption per month	Addiction Severity Index
Amount of money gained from illicit opioid consumption per month		Addiction Severity Index	
<b>Physical Health</b>	<i>Drug Cravings</i>	Craving for Opioid Substances	Subjective Opiate Withdrawal Scale German Version
			Visual Analog Scale for Heroin Craving
			Craving visual analogue scale (CVAS) (administered every week): a 10 cm line - with an end corresponding to 0 and the other to 100 - was used to record the extent of subjective cravings for heroin, cocaine and alcohol in the preceding week

Domains	Outcomes	Subdomains	Measurement of Outcome
			Tiffany Heroin Craving Questionnaire
	<i>Overdose</i>	Overdose of illicit or prescribed opioid and non-opioid substances requiring medical attention	Self-report Medical chart review
	<i>Withdrawal Symptoms</i>	Opioid physical withdrawal symptoms	The Withdrawal Symptoms Checklist Self-reported euphoric feelings The Addiction Severity Index Subjective Opiate Withdrawal Scale (German version: SOES) Self-report The Wang Scale Addiction Research Centre Inventory
	<i>General Physical Health</i>	General physical health and well-being, an assessment of current physical symptoms, physical functioning, physical role limitations, bodily pain, physical comorbidity as well as medical history	Opioid Treatment Index
Quality of Life scale (SF-12)			
Self reported health measured assessing symptoms, overdoses, and mortality			
Maudsley Addiction Profile			
Short Form 36-item Health Survey			
Physicians perception of disease severity and overall improvement compared to baseline		Clinical Global Impressions Scale German Version	
Immune system functioning	Plasma concentrations of TNF-alpha, IL-2 beta, IL-1beta and CD14 lymphocyte		
Cardiac Function assessed with corrected QT interval measurements	Electrocardiographic analysis		

Domains	Outcomes	Subdomains	Measurement of Outcome
		Evaluation of patients meetings the categorical QTc prolongation thresholds across treatment groups (e.g. more than 470 milliseconds for males and more than 490 milliseconds for females)	Electrocardiographic analysis
<b>Psychiatric Health and Symptoms</b>	<i>Psychiatric symptoms</i>	Psychiatric Assessment for Depression, Anxiety, and other psychiatric symptoms	Mental health symptoms measured using the SF-12
			Symptom checklist-90 (SCL-90)
			Short Form 36-item
			Self-rating depression (SRD) questionnaire
			Minnesota Multifactorial Personality Inventory (MMPI)
			Symptom checklist (SCL-5)
			The Beck Depression Inventory
			State Trait Anxiety Inventory (STAI)
			Sensation Seeking Scale (SSS)
			Addiction Severity Index
			Maudsley Addiction Profile
			Scale of Anhedonia Syndrome
			Self-reported assessments (somatization, depression, hostility, anxiety, paranoid ideation, interpersonal sensitivity)
<i>Psychological Adjustment</i>	Psychological and social adjustment	Addiction Severity Index (family and social relations scores)	
		Opiate Treatment Index (social functioning scores)	

Domains	Outcomes	Subdomains	Measurement of Outcome
			Clinical Global Impression as assessed by the Brief Psychiatric Rating Scale
<b>Global Quality of Life and Addiction Severity Assessments (outcomes of combined domains)</b>	<i>Composite Addiction Severity Scores</i>	Composite scores from addiction severity assessments that encompass patients physical, psychological, and social functioning, as well as their substance use behaviour	Composite International Diagnostic Interview
			European Addiction Severity Index Addiction Severity Index
	<i>Global Quality of Life</i>	Quality of life assessment encompasses the evaluations of physical, Social, physical, and psychological well-being	SCL-90-R subscales
			SCL-90-R global scores
			General Symptomatic Index
			Positive Symptom Total
			Positive Symptom Distress Index
			Lancashire Quality of Life Profile Visual Analog Scale (10 = very bad, 0 = very well) and with the temporal satisfaction with life scale (TSLs)
<b>Personal and Social Functioning</b>	<i>Criminal Behaviour</i>	Involvement in illegal activity	Self-reported days involved in illegal activities
			Self-reported time spent with: people still abusing substances, selling drugs, engaging in illegal activity
			Lifestyle Changes Questionnaire (patients indicated whether they had engaged in any of 9 activities to stop, reduce, or avoid cocaine/heroin use during the past week and whether they had committed crimes)

Domains	Outcomes	Subdomains	Measurement of Outcome
			Weekly Activity Summary (WAS 42)
	<i>Employment and Social Involvement</i>	Social stability assessed using current employment, volunteer, or social activities	Self-reported changes in vocational and social rehabilitation
			Self-reported consumption of meals, type of accommodation, and current employment activities
			Weekly Activity Summary (WAS 42)
			Behavioural observation where the research assistant recorded (yes/no) if patients had initiated new activities or increased the amount of time spent in any of three activity categories: (1) employment; (2) family/social; and (3) personal (spiritual, counselling or psychotherapy, physical fitness)
			Participation in non-study related addiction treatment programs (Narcotics Anonymous, e.c.t)
	<i>Relationships</i>	Evaluation of relationships and personal conflict with others	Personal and social functioning domain of the Maudsley Addiction Profile
			Social functioning measured using SF-36 health survey
			Personal and social function measured by self-reported time spent with people still abusing substances, selling drugs, engaging in illegal activity
	<i>Personal Stability</i>	Evaluation of personal stability through assessment of housing and food consumption	Self-reported consumption of meals and type of accommodation
<b>Resource Utilization</b>	<i>Service utilization</i>	Evaluation of how patients utilize available treatment and social	Days Patients were seen by counsellors

Domains	Outcomes	Subdomains	Measurement of Outcome	
		services	Total clinic attendance	
<b>Intervention Adherence</b>	<i>Retention in Treatment</i>	Number of patients remaining on the allocated intervention at the end of follow-up	Adjudicated by the trial research staff	
		Number of patients remaining on the allocated intervention, and maintained a standard of opioid-free urine set by the study coordinators at the end of follow-up	Adjudicated by the trial research staff	
		Time until patient withdraws from treatment	Adjudicated by the trial research staff	
	<i>Intervention Compliance</i>	Days patients attended clinic as an assessment of how well patient adheres to the treatment regime		Adjudicated by the trial research staff
				Treatment attendance, the number of days medicated divided by days in treatment
				Involvement of a significant other in treatment who was asked to supervise and report on compliance at each study visit, either in person or by telephone
Assessment of medication adherence (evaluation of whether patient takes the medication prescribed)		Visual inspection of urine, inclusion of riboflavin 50 mg in the active and placebo naltrexone capsules with visual inspection for its presence using ultraviolet light at the long wave setting (444 nm) in a room with low ambient light		
		Count of remaining capsules at each appointment		

Domains	Outcomes	Subdomains	Measurement of Outcome
			Study patients were required to respond to a random medication recall once each 4 weeks to monitor and deter potential misuse of methadone
		Involvement in services provided by treatment centres	Assessment of the counselling visits, which were based on the length (minutes) and number of contacts the patient had with either individual or group treatments
	<i>Successful Medication Induction</i>	At least one dose of medication by the 6th day of the study	Assessed by clinical research staff
<b>Intervention Acceptance</b>	<i>Intervention Preference</i>	Assessment of final drug of choice (at end of cross-over trial participants could chose which therapy to remain on)	Self-report
		Medication preferences (includes a proxy assessment of dosing adequacy)	The Helping Alliance Questionnaire II (HAq-II; patient version), which is a 19-question self-administered instrument that measures the quality of therapeutic alliance between patients and therapists from the point of view of the patients
			The Client Satisfaction Questionnaire (CSQ), a self-administered questionnaire that assesses overall satisfaction with treatment

Domains	Outcomes	Subdomains	Measurement of Outcome
			Measured using a visual analogue questionnaire of drug properties which required them to “rate each drug on six different factors: is the drug holding (suppressing withdrawal); how much buzz do you get from the drug; do you experience side effects, do the side effects bother you; do you like the drug, and do you feel more normal?”

**Table 2.** Verbatim Answers to Qualitative Interview to Understand Goals of Therapy

Participant	Verbal Answer
1	Remain abstinent from drugs
2	I don't want to use drugs
3	Not use street drugs
4	Get off opioids completely
5	Maintain my job
6	Just get my life back; I'm still an addict and I don't want that to sneak back on me
7	To not be sick anymore
8	Being completely off drugs. To never touch drugs again
9	Being able to control my addiction. Just living a life without having to take medication everyday
10	Not to use drugs
11	Being independent from methadone and drugs
12	Pain control
13	To get off methadone and never look back at any opioids
14	Managing my addictive personality, whether it is a drug addiction or not
15	Get clean; not going back on opioid and not go back on Suboxone
16	Become drug free
17	Get off methadone; Be done with this all
18	Get off it (methadone) completely

**Table 3: Patient's Response to Predetermined Treatment Goals**

<b>Participant</b>	<b>Outcome #1</b>	<b>Outcome #2</b>	<b>Outcome #3</b>	<b>Outcome #4</b>
1	Money spent on drugs	Overdose	Injecting	N/A
2	Stable relationships	Coping	N/A	N/A
3	Employment	Housing	Depression	
4	Stable relationships	Money spent on drugs	Sexual function	Money spent on drugs
5	Employment	Stable relationships	Housing	N/A
6	Abstinence from opioid use	Employment	N/A	N/A
7	Regaining physical health	Abstinence from opioid use	N/A	N/A
8	Abstinence from opioid use	Regaining physical health	Coping	N/A
9			Missing Data	
10	Abstinence from opioid use	Depression	Coping	N/A
11	Abstinence from opioid use	Drug craving	Money Spent on drugs	Regaining physical health
12	Pain	Employment	N/A	N/A
13	Abstinence from opioid use	Money spent on drugs	Drug Craving	Stable relationships
14	Drug craving	Stable relationship	Money spent on drugs	N/A
15	Drug craving	Pain		
16	Abstinence from opioid use	Pain	Stable relationships	Drug craving
17	Abstinence from opioid use	Money spent on drugs	Depression	Anxiety
18	Abstinence from opioid use	Drug craving	Stable relationships	N/A

## Figures





Figure 1

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.



**Caption:** Patients ranking of treatment goals from a “pre-determined” list provided during the qualitative interview. Patients were asked them to rank which aspect of recovery meant the most to their addiction treatment. Patients were allowed to rank up to four items. The figure above illustrates the first ranked items.

## Figure 2

First Ranked Treatment Goals Among Patient’s Receiving OSAT.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplement1.doc](#)
- [supplement2.pdf](#)
- [supplement3.pdf](#)